BioCentury
ARTICLE | Company News

Take2 licenses Grail’s nasopharyngeal cancer detection platform

May 8, 2019 8:52 PM UTC

Grail Inc. (Menlo Park, Calif.) granted Take2 Health Ltd. (Hong Kong, China) exclusive, worldwide rights to a portfolio of technology for the early detection of nasopharyngeal cancer. Financial terms were not disclosed.

Grail spokesperson Charlotte Arnold told BioCentury the company gained the technology in 2017 when it acquired cancer diagnostics developer Cirina Ltd. Cirina co-founder Dennis Lo, who invented the tech, joined Grail as a scientific co-founder and member of its scientific advisory board following the merger (see "Grail Merging with Cirina")...

BCIQ Company Profiles

Grail Inc.